Allogene Therapeutics (Allogene Therapeutics) Momentum Rank : 10 (As of Apr. 26, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics Momentum Rank?

Allogene Therapeutics has the Momentum Rank of 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Allogene Therapeutics's Momentum Rank

For the Biotechnology subindustry, Allogene Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allogene Therapeutics's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's Momentum Rank falls into.

Allogene Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics (Allogene Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.allogene.com

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Executives

Deborah M. Messemer	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker	officer: CHIEF FINANCIAL OFFICER	15 RIORDAN PLACE, MENLO PARK CA 94025
Earl Martin Douglas	officer: GENERAL COUNSEL	BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Yinlin Jack Chen	officer: SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Timothy L. Moore	officer: Chief Technical Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Lillian Smith	officer: VP, Corporate Counsel	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri	officer: General Counsel	C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Zachary Roberts	officer: EVP of R&D	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado	officer: EVP of R&D and CMO	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore	officer: Chief Technical Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Eric Thomas Schmidt	officer: Chief Financial Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang	director, officer: President and CEO	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004